GPP
RARE icon

Great Point Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Great Point Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20M Buy
+600,000
New +$14.9M 3.79% 9

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Great Point Partners's RARE Position: Q1 2026 in Review

Great Point Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 300,000 shares — an estimated $6.9M sold.

Great Point Partners first reported a position in RARE in Q4 2022 and held it in 6 quarters. The position peaked at $31.2M in Q2 2023. 298 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Great Point Partners reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Great Point Partners sold 300,000 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $6.9M.
  • Great Point Partners first reported a position in Ultragenyx Pharmaceutical in Q4 2022 and held it in 6 quarters.
  • Great Point Partners's Ultragenyx Pharmaceutical position peaked at $31.2M in Q2 2023.
  • 298 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Great Point Partners's 13F filing for Q1 2026, filed 15 May 2026.